Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.

Abstract excerpt

Minimal residual disease (MRD) testing in acute myeloid leukemia is increasingly being used to assess treatment response and stratify the risk of relapse for individual patients. Molecular methods for MRD testing began with PCR-based assays for individual recurrent mutations. To date, there is robust evidence for testing NPM1, CBFB-MYH11, and RUNX1/RUNXT1 mutations using this approach, though the best timing and...

Topics

Join the communities discussing this publication.

• Biomarkers, Tumor
• MYH11 gene
• RUNX1 gene
• High-Throughput Nucleotide Sequencing
• Leukemia, Myeloid, Acute